US President Donald Trump has once again created a stir in the world. Trump announced a mutual tariff from the White House on Wednesday. America will impose a 10 percent Aadhaar tariff on all countries. The US has increased tariffs on many countries. According to the US, India imposes 52% tariff on American imports, so now it will have to face a counter -tariff of 26%. But there is one thing in this tariff war that Trump did not dare to touch and India will benefit greatly. Trump has excluded the pharmaceutical sector from it. The US did not dare to put tariffs on drugs because it knew that its effect would be terrible. Apart from the tariff war, it also reflects Trump’s compulsion.
A statement issued by the White House said that products such as pharmaceuticals, copper, semiconductor and wood have been exempted from tariffs. According to 2023 data, the United States imports drugs worth $ 170 billion every year. Countries like India have to play a big role in it. According to an Economic Times report, Raja Bhanu, Director General of the Indian Drug Export Promotion Council, says that India exports goods worth more than $ 8 billion to the US every year. Generic medicines are an important part of the drug supply.
India is solving America’s disease
Trump knows that if he had put a tariff on medicines, it would have been a huge burden on American people. Rising prices of drugs can cause crisis in hospitals, which will lead to American people on the streets. Trump does not want to take such a risk, especially when medical care in the US is already a sensitive issue. If we talk about the most exporting pharmaceutical companies from India, then they include Sun Pharma, Aurobindo Pharma, Dr. Reddy’s Labs, Cipla and Lupine. These companies have a large stake in India’s total pharma exports and provide cheap medicines to the US.
The post This is the region of India on which Trump did not dare to put tariff first appeared on News India Live | Breaking India News, The Indian Headline, India Express News, Fast India News.
